WO2007025274A3 - Self-assembling nanoparticles for the treatment of vascular diseases - Google Patents
Self-assembling nanoparticles for the treatment of vascular diseases Download PDFInfo
- Publication number
- WO2007025274A3 WO2007025274A3 PCT/US2006/033633 US2006033633W WO2007025274A3 WO 2007025274 A3 WO2007025274 A3 WO 2007025274A3 US 2006033633 W US2006033633 W US 2006033633W WO 2007025274 A3 WO2007025274 A3 WO 2007025274A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- self
- binding
- assembling nanoparticles
- composition
- treatment
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 7
- 208000019553 vascular disease Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 3
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000017423 tissue regeneration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6941—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a granulate or an agglomerate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2201/00—Properties
- C08L2201/12—Shape memory
Abstract
The present invention is directed to the formation of structures in situ through the principles of ligand binding. These structures are efficacious, for example, for tissue repair as well as for short- and long-term disease and condition management. According to one aspect of the invention, an injectable composition comprising self-assembling nanoparticles is provided. The self-assembling nanoparticles include: (a) a nanoparticle portion, (b) tissue binding ligands attached to the nanoparticle portion, which cause preferential binding and accumulation of the nanoparticles at one or more targeted tissue locations upon injection of the composition into the body, and (c) first and second interparticle binding ligands attached to the nanoparticle portion, which cause interparticle binding upon injection of the composition into the body.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008528244A JP2009506074A (en) | 2005-08-25 | 2006-08-25 | Self-assembled intravascular structures |
EP06802522A EP1928434A2 (en) | 2005-08-25 | 2006-08-25 | Self-assembling nanoparticles for the treatment of vascular diseases |
CA002622904A CA2622904A1 (en) | 2005-08-25 | 2006-08-25 | Self-assembling nanoparticles for the treatment of vascular diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/211,809 | 2005-08-25 | ||
US11/211,809 US20070048383A1 (en) | 2005-08-25 | 2005-08-25 | Self-assembled endovascular structures |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007025274A2 WO2007025274A2 (en) | 2007-03-01 |
WO2007025274A3 true WO2007025274A3 (en) | 2007-07-26 |
Family
ID=37772521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/033633 WO2007025274A2 (en) | 2005-08-25 | 2006-08-25 | Self-assembling nanoparticles for the treatment of vascular diseases |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070048383A1 (en) |
EP (1) | EP1928434A2 (en) |
JP (1) | JP2009506074A (en) |
CA (1) | CA2622904A1 (en) |
WO (1) | WO2007025274A2 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (en) | 2003-07-31 | 2005-02-01 | Univ Roma | PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA. |
GB0329654D0 (en) * | 2003-12-23 | 2004-01-28 | Smith & Nephew | Tunable segmented polyacetal |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
JP5059312B2 (en) * | 2005-09-16 | 2012-10-24 | Hoya株式会社 | Highly dispersible calcium phosphate compound nanoparticles and method for producing the same |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
US20090104433A1 (en) * | 2006-05-18 | 2009-04-23 | Jifan Li | Materials having variable electrical properties based upon environmental stimuli |
EP2061434A2 (en) * | 2006-09-08 | 2009-05-27 | The Regent of the University of California | Engineering shape of polymeric micro-and nanoparticles |
DE602007011671D1 (en) * | 2006-11-30 | 2011-02-10 | Smith & Nephew Inc | FIBER REINFORCED COMPOSITE MATERIAL |
US8372427B2 (en) * | 2007-03-05 | 2013-02-12 | Abbott Cardiovascular Systems Inc. | Therapeutic composition with enhanced endothelium targeting |
US20100021985A1 (en) * | 2007-03-20 | 2010-01-28 | The Regents Of The University Of California | Mechanical process for creating particles in fluid |
WO2008115550A1 (en) * | 2007-03-20 | 2008-09-25 | The Regents Of The University Of California | Mechanical process for creating particles in a fluid |
AU2008240418B2 (en) | 2007-04-18 | 2013-08-15 | Smith & Nephew Plc | Expansion moulding of shape memory polymers |
ATE505220T1 (en) | 2007-04-19 | 2011-04-15 | Smith & Nephew Inc | GRAFT FIXATION |
EP2142227B1 (en) | 2007-04-19 | 2012-02-29 | Smith & Nephew, Inc. | Multi-modal shape memory polymers |
WO2009012443A1 (en) * | 2007-07-18 | 2009-01-22 | The Board Of Trustees Of The University Of Illinois | Nanoparticles for the elution of growth factors for recovery and regeneration of organs |
US20090043276A1 (en) * | 2007-08-09 | 2009-02-12 | Boston Scientific Scimed, Inc. | Drug delivery device, compositions and methods relating thereto |
US20090047318A1 (en) * | 2007-08-16 | 2009-02-19 | Abbott Cardiovascular Systems Inc. | Nanoparticle-coated medical devices and formulations for treating vascular disease |
US8722623B2 (en) * | 2007-09-17 | 2014-05-13 | University Of Maryland, Baltimore | Compositions and methods utilizing fibrin beta chain fragments |
US9216220B2 (en) * | 2008-04-10 | 2015-12-22 | Board Of Regents, The University Of Texas System | Compositions and methods for thermo-sensitive nanoparticles and magnetic nanoparticles |
US20110177154A1 (en) * | 2008-09-15 | 2011-07-21 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Tubular nanostructure targeted to cell membrane |
US20100068523A1 (en) * | 2008-09-16 | 2010-03-18 | Aveka, Incorporated | Surface modification of and dispersion of particles |
ES2335852B1 (en) * | 2008-10-02 | 2011-02-28 | Universidad De Sevilla | USE OF NANOPARTICULES OF NOBLE METALS AS IMMUNOMODULATORS AND IMMUNOMODULATING COMPOSITION. |
CA2740125A1 (en) | 2008-10-09 | 2010-04-15 | Northeastern University | Multifunctional self-assembling polymeric nanosystems |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US9115336B2 (en) * | 2010-05-25 | 2015-08-25 | Muffin Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
US9828603B2 (en) | 2012-08-13 | 2017-11-28 | Cedars Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US9457128B2 (en) | 2012-09-07 | 2016-10-04 | President And Fellows Of Harvard College | Scaffolds comprising nanoelectronic components for cells, tissues, and other applications |
US9786850B2 (en) * | 2012-09-07 | 2017-10-10 | President And Fellows Of Harvard College | Methods and systems for scaffolds comprising nanoelectronic components |
US20160220734A1 (en) * | 2013-10-02 | 2016-08-04 | The Regents Of The University Of Colorado, A Body Corporate | Photo-active and radio-opaque shape memory polymer-gold nanocomposite materials for trans-catheter medical devices |
US10182985B2 (en) * | 2014-06-11 | 2019-01-22 | Massachusetts Institute Of Technology | Residence structures and related methods |
AU2015327812B2 (en) | 2014-10-03 | 2021-04-15 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
US10463871B2 (en) | 2015-02-25 | 2019-11-05 | Weinberg Medical Physics Inc | Apparatus and method for medical image-guided 3-D printing within a body |
CN108472249A (en) | 2015-10-23 | 2018-08-31 | 林德拉有限公司 | Stomach resident system and its application method for therapeutic agent sustained release |
US11253551B2 (en) | 2016-01-11 | 2022-02-22 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
AU2017336154B2 (en) | 2016-09-30 | 2023-11-09 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
WO2018195210A1 (en) | 2017-04-19 | 2018-10-25 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
WO2020190590A1 (en) * | 2019-03-15 | 2020-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Monocyte-selective drug delivery system using single-walled carbon nanotubes to induce efferocytosis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030157325A1 (en) * | 2002-02-20 | 2003-08-21 | International Business Machines Corporation | Monodisperse nanoparticle containing thin films via self-assembly |
WO2004063705A2 (en) * | 2003-01-08 | 2004-07-29 | University Of Massachusetts | Liquid-liquid interfacial nanoparticle assemblies |
US20040191517A1 (en) * | 2003-03-26 | 2004-09-30 | Industrial Technology Research Institute | Self-assembling nanowires |
WO2004088313A1 (en) * | 2003-04-02 | 2004-10-14 | Tero Soukka | Nanoparticle for bioaffinity assays |
US20060140871A1 (en) * | 2004-11-30 | 2006-06-29 | Sillerud Laurel O | Magnetic resonance imaging of prostate cancer |
US20060148016A1 (en) * | 2003-04-02 | 2006-07-06 | Tero Soukka | Nanoparticle for bioaffinity assays |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
US5780010A (en) * | 1995-06-08 | 1998-07-14 | Barnes-Jewish Hospital | Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system |
EP0975691B1 (en) * | 1997-04-21 | 2010-10-13 | California Institute Of Technology | Multifunctional polymeric coatings |
CA2288292A1 (en) * | 1997-04-24 | 1998-10-29 | Nycomed Imaging As | Embolus therapy using insoluble microparticles or vesicles containing contrast agents |
GB9721901D0 (en) * | 1997-10-16 | 1997-12-17 | Univ Manchester | Particles |
DK1062278T3 (en) * | 1998-02-23 | 2006-09-25 | Mnemoscience Gmbh | Polymers with shape memory |
DE59914547D1 (en) * | 1998-07-15 | 2007-12-20 | Max Planck Gesellschaft | POLYELECTROLYTHOULES ON BIOLOGICAL TEMPLATES |
AU777844B2 (en) * | 1999-04-16 | 2004-11-04 | Children's Medical Center Corporation | Adhesion modulatory peptides and methods for use |
DE60000622T2 (en) * | 1999-06-10 | 2003-02-27 | Max Planck Gesellschaft | ENCLOSURE OF CRYSTALS WITH A MULTILAYER COATING |
ES2263485T3 (en) * | 1999-09-14 | 2006-12-16 | Biogen Idec Ma Inc. | THERAPY FOR CHRONIC RENAL INSUFFICIENCY USING ONE OR MORE INTEGRIN ANGTAGONISTS. |
DE10001172A1 (en) * | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templating solid particles with polymer multilayers |
AU2001231099A1 (en) * | 2000-01-24 | 2001-07-31 | Smart Therapeutics, Inc. | Thin-film shape memory alloy device and method |
US20020043456A1 (en) * | 2000-02-29 | 2002-04-18 | Ho Ken K. | Bimorphic, compositionally-graded, sputter-deposited, thin film shape memory device |
US20040146862A1 (en) * | 2000-03-15 | 2004-07-29 | Eos Biotechnology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
US6790298B2 (en) * | 2000-07-10 | 2004-09-14 | Tini Alloy Company | Method of fabrication of free standing shape memory alloy thin film |
ATE273067T1 (en) * | 2000-08-02 | 2004-08-15 | Max Planck Gesellschaft | POLYELECTROLYTE CAPSULE PRODUCTION BY SURFACE PRECIPITATION |
ATE295156T1 (en) * | 2000-08-28 | 2005-05-15 | Max Planck Gesellschaft | MULTI-LAYER POLYELECTROLYTE CAPSULES WITH CONTROLLED AND SUSTAINED RELEASE |
US7462366B2 (en) * | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US6746890B2 (en) * | 2002-07-17 | 2004-06-08 | Tini Alloy Company | Three dimensional thin film devices and methods of fabrication |
US7588825B2 (en) * | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
US7364585B2 (en) * | 2003-08-11 | 2008-04-29 | Boston Scientific Scimed, Inc. | Medical devices comprising drug-loaded capsules for localized drug delivery |
US20050238870A1 (en) * | 2004-04-22 | 2005-10-27 | Marcia Buiser | Embolization |
US7767220B2 (en) * | 2004-04-23 | 2010-08-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical articles having covalently modified, biocompatible surfaces |
-
2005
- 2005-08-25 US US11/211,809 patent/US20070048383A1/en not_active Abandoned
-
2006
- 2006-08-25 JP JP2008528244A patent/JP2009506074A/en active Pending
- 2006-08-25 CA CA002622904A patent/CA2622904A1/en not_active Abandoned
- 2006-08-25 WO PCT/US2006/033633 patent/WO2007025274A2/en active Application Filing
- 2006-08-25 EP EP06802522A patent/EP1928434A2/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030157325A1 (en) * | 2002-02-20 | 2003-08-21 | International Business Machines Corporation | Monodisperse nanoparticle containing thin films via self-assembly |
WO2004063705A2 (en) * | 2003-01-08 | 2004-07-29 | University Of Massachusetts | Liquid-liquid interfacial nanoparticle assemblies |
US20040191517A1 (en) * | 2003-03-26 | 2004-09-30 | Industrial Technology Research Institute | Self-assembling nanowires |
WO2004088313A1 (en) * | 2003-04-02 | 2004-10-14 | Tero Soukka | Nanoparticle for bioaffinity assays |
US20060148016A1 (en) * | 2003-04-02 | 2006-07-06 | Tero Soukka | Nanoparticle for bioaffinity assays |
US20060140871A1 (en) * | 2004-11-30 | 2006-06-29 | Sillerud Laurel O | Magnetic resonance imaging of prostate cancer |
Non-Patent Citations (1)
Title |
---|
SHCHUKIN D G ET AL: "Micron-scale hollow polyelectrolyte capsules with nanosized magnetic Fe3O4 inside", MATERIALS LETTERS, NORTH HOLLAND PUBLISHING COMPANY. AMSTERDAM, NL, vol. 57, no. 11, March 2003 (2003-03-01), pages 1743 - 1747, XP004411773, ISSN: 0167-577X * |
Also Published As
Publication number | Publication date |
---|---|
JP2009506074A (en) | 2009-02-12 |
EP1928434A2 (en) | 2008-06-11 |
WO2007025274A2 (en) | 2007-03-01 |
US20070048383A1 (en) | 2007-03-01 |
CA2622904A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007025274A3 (en) | Self-assembling nanoparticles for the treatment of vascular diseases | |
WO2008021908A3 (en) | Multistage delivery of active agents | |
WO2007076295A3 (en) | Nanoclusters for delivery of therapeutics | |
WO2009102467A3 (en) | Devices, formulations, and methods for delivery of multiple beneficial agents | |
WO2004111192A3 (en) | Targeted delivery to legumain-expressing cells | |
EP2985281A3 (en) | Isoindoline compounds for use in the treatment of cancer | |
WO2006122046A3 (en) | Vascular disease therapies | |
WO2005016266A3 (en) | Methods for treating cardiovascular disease using a soluble ctla4 molecule | |
EP2481402A3 (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
WO2007002572A3 (en) | Nattokinase for reducing whole blood viscosity | |
WO2004096998A3 (en) | Nanoparticular tumor targeting and therapy | |
WO2005084637A3 (en) | Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof | |
TW200800975A (en) | New compounds 2 | |
WO2006069782A3 (en) | Lipid complexes coated with peg and their use | |
WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
WO2002002638A3 (en) | Methods for treating rheumatic diseases using a soluble ctla4 molecule | |
WO2006060815A3 (en) | Fibrous structures comprising a nanoparticle additive | |
WO2006011810A3 (en) | Mr imaging method for the discrimination between healthy and tumour tissue | |
WO2006039704A3 (en) | Pharmaceutical composition and method for treating a joint capsule arthropathy | |
WO2006029845A3 (en) | Delivery vehicle containing nanoparticles | |
WO2007034188A3 (en) | Chemo-immunotherapy method | |
WO2007056525A3 (en) | High affinity siglec ligands | |
BRPI0508233A (en) | isoquinoline derivatives and methods for their use | |
WO2007044085A3 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
WO2003034995A3 (en) | Integrin targeting compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2622904 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008528244 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006802522 Country of ref document: EP |